Sibutramine (or MERIDIA®) was mainly prescribed to treat obesity.
Class: Anorectic, Serotonin-norepinephrine Reuptake Inhibitor (SNRI),
FDA Approval: 1997
Dosage Forms: 5 mg, 10 mg, 15 mg
Biological Half-life: 1 hour (sibutramine), 14 hours (M1), 16 hours (M2)
Side Effects: Dizziness, blurred vision, dry mouth, nausea, insomnia, constipation, appetite changes, flushing, muscle/joint pain, high blood pressure, tachycardia
Routes of Administration: Oral
Pregnancy Category: C (US)